MYTELASE
LOE ApproachingNDAORALTABLET
Approved
May 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYTELASE is an oral small-molecule tablet approved in 1956 for an unknown indication under Sanofi sponsorship. The mechanism of action and specific therapeutic use remain undocumented in available data, limiting assessment of clinical positioning.
LOE Approaching
LOE-stage product approaching patent expiration suggests reduced team investment and focus on generic transition management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring and limited growth potential on this asset. Career moves on MYTELASE are best suited for professionals seeking to manage mature products through LOE transitions or support generic entry strategies.
Brand ManagerCommercial Operations Manager
Worked on MYTELASE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.